Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Items 801–900 of 1,000
Qu, F.-J., Wu, S., & Kong, Y. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.902 · Cited by 5
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023
Mansor, E. A., Mahoney, M., Chénard-Poirier, M., Ramjeesingh, R., Nair, V. J., Kennedy, E. D., Locke, G. E., Welch, S. A., Berry, S. R., Couture, F., et al. (2023) · Current Oncology · doi:10.3390/curroncol30090593 · Cited by 5
Popescu, I., Dudau, A.-M., Dima, S., Herlea, V., Croitoru, V. M., Dinu, I. M., Miron, M. I., Lupescu, I. G., Cazacu, I. M., Dumitru, R. L., et al. (2024) · Medicina · doi:10.3390/medicina60050696 · Cited by 5
Fruquintinib in refractory metastatic colorectal cancer: a multicenter real-world study
Xu, D., Zeng, S., Qiu, W., Wang, G., Qin, Z., Liu, Y., Zhou, S., Zhang, Z., Chang, W., Feng, Q., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103702 · Cited by 6
Aprile, G., Rihawi, K., Scartozzi, M., & Bordonaro, R. (2015) · Future Oncology · doi:10.2217/fon.15.213 · Cited by 5
Hsu, H., Chou, W., Kuan, F., Lee, K., Rau, K.-M., Huang, J., & Yang, T. (2018) · Cancer Management and Research · doi:10.2147/cmar.s179345 · Cited by 5
Price, T. J., Burge, M., Chantrill, L. A., Gibbs, P., Pavlakis, N., Shapiro, J. D., & Sjoquist, K. M. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13336 · Cited by 6
Gao, Z., Cao, C., Bao, Y., Fan, Y., Chen, G., & Fu, P. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820943241 · Cited by 5
Wang, L., Cao, H., Jiang, C., He, W., You, Y., Peng, K., Jin, Y., & Xia, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.587692 · Cited by 6
Antoniotti, C., Moretto, R., Rossini, D., Masi, G., Falcone, A., & Cremolini, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102135 · Cited by 6
Self-citationKoopman, M., Pinto, C., Bodoky, G., García‐Carbonero, R., Marti, F. M., & Bachet, J. (2022) · Future Oncology · doi:10.2217/fon-2021-1333 · Cited by 5
Hsieh, M., Rau, K., Lin, S.-E., Liu, K.-W., Chiu, C., Chen, C., Song, L., & Chen, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.867546 · Cited by 5
Chennamadhavuni, A., & Kasi, P. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847299 · Cited by 5
Kourié, H. R., Ibnshamsah, F., Zouein, J., Naim, N., Abbasi, S., Allahloubi, N. M. A., Al-Naqqash, M. A., Alolayan, A. A. M., Alshehri, A., Bitar, N., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0282 · Cited by 6
Özet, A., Dane, F., Aykan, N. F., Yalçın, Ş., Evrensel, T., Özkan, M., Karabulut, B., Ormeci, M. N., Atasev, O., Vidot, L., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0455 · Cited by 5
Arrichiello, G., Perrone, A., Napolitano, S., Martini, G., Falco, V. D., Incoronato, P., Laterza, M. M., Facchini, G., Famiglietti, V., Nacca, V., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00916-8 · Cited by 5
Cosso, F., Lavacchi, D., Fancelli, S., Caliman, E., Brugia, M., Rossi, G., Winchler, C., Pillozzi, S., & Antonuzzo, L. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001410 · Cited by 5
Calegari, M. A., Zurlo, I. V., Dell’Aquila, E., Basso, M., Orlandi, A., Bensi, M., Camarda, F., Anghelone, A., Pozzo, C., Sperduti, I., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.06.002 · Cited by 7
The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
Martínez‐Pérez, J., Martínez, M. C. R., & García‐Carbonero, R. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1475557 · Cited by 5
Koseki, J., Konno, M., Asai, A., Horie, N., Tsunekuni, K., Kawamoto, K., Obika, S., Doki, Y., Mori, M., & Ishii, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-57899-7 · Cited by 5
Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 6
Self-citationUboha, N. V., Lubner, S. J., LoConte, N. K., Mulkerin, D. L., Eickhoff, J. C., & Deming, D. A. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00929-y · Cited by 5
Suzuki, N., Nakagawa, F., & Takechi, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.6258 · Cited by 5
Treatment sequencing of metastatic colorectal cancer based on primary tumor location
Temraz, S. N., Mukherji, D., Nassar, F. J., Moukalled, N. M., & Shamseddine, A. I. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.05.001 · Cited by 5
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial
Vandeputte, C., Bregni, G., Gkolfakis, P., Guiot, T., Pretta, A., Kehagias, P., Senti, C., Reina, E. A., Bogaert, C. V., Deleporte, A., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.07.006 · Cited by 5
Self-citationJo, H., Lee, M., Lee, Y.-P., Kim, H.-S., Hong, J. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., et al. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.02.011 · Cited by 5
Treatment of Rectal Cancer in Older Adults
Sheikh, A. R., Yameen, H., & Hartshorn, K. L. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0746-2 · Cited by 7
Stintzing, S., & Heinemann, V. (2019) · Forum · doi:10.1007/s12312-019-0657-7 · Cited by 5
Suzuki, N., Nakagawa, F., & Takechi, T. (2021) · Oncology Letters · doi:10.3892/ol.2021.12772 · Cited by 5
TAS-102 and the quest for predictive biomarkers
Velden, D. L. V. D., Opdam, F. L., & Opdam, F. L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000263 · Cited by 5
Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102
Kasi, P. M., & Grothey, A. F. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.001 · Cited by 6
Third-Line Therapy in Metastatic Colorectal Cancer
van de Haar, J., Valeri, N., & Voest, E. E. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2306486 · Cited by 5
Marques, D. S., Costa, A. L., Mansinho, A., Quintela, A., Pratas, E., Brito-da-Silva, J., Cruz, J. J., Félix, J., Rodrigues, J. M., Mota, M., et al. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.07.004 · Cited by 4
Delphi consensus for the third-line treatment of metastatic colorectal cancer
Alfonso, P. G., Vera, R., Aranda, E., Élez, E., & Rivera, F. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03369-1 · Cited by 4
A Revisit on FDA Approved Anticancer Drugs (1949 – 2024)
Myla, L. S., & Gope, E. R. (2024) · Journal of Pharma Insights and Research. · doi:10.69613/k20qe441 · Cited by 4
Hsiao, K., Chen, H., Rau, K.-M., Liu, K.-W., Shia, B., Chang, W.-S., Liang, H.-Y., & Hsieh, M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae235 · Cited by 4
Predicting long-term survival among patients with HCC
Goldberg, D. S., Reese, P. P., Kaplan, D. A., Zarnegarnia, Y., Gaddipati, N., Gaddipati, S., John, B. V., & Blandon, C. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000581 · Cited by 5
Rubio, P. S., Corpa, A. M. B., Navarro, V. A., Rodríguez, P. P. D. A., Moreno-Doval, J., Pérez, J. C. C., Serrano, P. G., Merino, C. G., Suero, C. G. D. Q., Fradejas, J. F., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1446945 · Cited by 5
Ahn, D. H., Bekaii‐Saab, T., Yuan, C., Kurtinecz, M., Pan, X., Vassilev, Z. P., Pisa, F. E., & Ostojic, H. (2025) · Cancers · doi:10.3390/cancers17060969 · Cited by 5
Kim, H., Shin, K., An, H. J., Kim, I.-H., Bae, J. H., Lee, Y. S., Lee, I. K., Lee, M. A., & Park, S. J. (2025) · Biomedicines · doi:10.3390/biomedicines13040976 · Cited by 5
Chiang, N., Bai, L., Ho, I., Hsu, C., Liang, Y., Chiu, C., Lin, C., Chang, K.-Y., Chen, S.-H., Tsai, H., et al. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01547-2 · Cited by 4
Huyghe, N. D., Benidovskaya, E., Masoodi, T., Sinapi, I., Cuyper, A. D., Vempalli, F. R., Beyaert, S. P., Bouzin, C., Osorio, F. M., Ferraro, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102201 · Cited by 6
Gao, Z., Wang, X.-Y., Song, T., Shen, Z.-G., Wang, X.-Y., Wu, S.-K., & Jin, X. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i29.109947 · Cited by 4
Xu, Y., Wang, D., & Xu, Y. (2025) · Cancer Medicine · doi:10.1002/cam4.71352 · Cited by 4
Sokołowski, M., & Butrym, A. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211101 · Cited by 6
Harnessing epigenetics: Genome-wide DNA methylation assay for colorectal cancer therapy
Ishioka, C. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103062 · Cited by 5
Liu, C., Nie, J., Li, S., Ma, S., Su, D., Ma, Z., Tang, J., Zhang, C., Lou, C., Su, J., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218238 · Cited by 4
Pakvisal, N., Pappas, L., Caughey, B. A., Horick, N., Tarazona, N., Vora, K. B., Ouyang, B., Pandey, A., Peacker, B. L., Sun, J., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0690 · Cited by 4
Matsumoto, T., Yamamura, S., Ikoma, T., Kurioka, Y., Doi, K., Yasuda, T., Boku, S., Kawai, T., Shibata, N., Nagai, H., et al. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221137135 · Cited by 4
Salvatore, L., Bensi, M., Vivolo, R., Zurlo, I. V., Dell’Aquila, E., Grande, R., Anghelone, A., Emiliani, A., Citarella, F., Calegari, M. A., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1125013 · Cited by 6
Sapir, E., Pfeffer, R., Wygoda, M. R., Purim, O., Levy, A., Corn, B. W., Amitay, Y., Ohana, P., & Gabizón, A. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.03.046 · Cited by 4
Zöhrlaut, L. K., Karthaus, M., Vehling‐Kaiser, U., von Kunhardt, L., Stintzing, S., Heinemann, V., & von Einem, J. C. (2023) · Oncology Research and Treatment · doi:10.1159/000531268 · Cited by 4
Revolutionizing KRAS p.G12C therapy in metastatic colorectal cancer: The triumph of dual inhibition
Ottaiano, A., & Santorsola, M. (2023) · Med · doi:10.1016/j.medj.2023.11.005 · Cited by 4
Kinos, S., Hagman, H., Halonen, P., Soveri, L., O’Reilly, M., Pfeiffer, P., Frödin, J., Sørbye, H., Heervä, E., Liposits, G. I., et al. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.24023 · Cited by 4
Boland, P. M., Mukherjee, S., Imanirad, I., Vijayvergia, N., Cohen, S. D., Gupta, M., Iyer, R. V., Bakin, A. V., Wang, J., Chatley, S., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02845-x · Cited by 4
Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
Kang, D.-W., Lynn, P. B., Wang, L., Zhou, S., & Shen, C. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00529-z · Cited by 4
Boland, P. M., Lenz, H., Ciombor, K. K., Florou, V., Pishvaian, M. J., Cusnir, M., Cohen, D. J., Guo, J. Y., Tang, M., Rajagopalan, P., et al. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01489-1 · Cited by 11
Self-citationSignorelli, C., Calegari, M. A., Anghelone, A., Passardi, A., Gallio, C., Bittoni, A., Lucchetti, J., Angotti, L., Giacomo, E. D., Zurlo, I. V., et al. (2025) · Cancers · doi:10.3390/cancers17122037 · Cited by 5
Wakabayashi, M., Taniguchi, H., Makiyama, A., Sunakawa, Y., Takeda, H., Arimizu, K., Okumura, Y., Inagaki, C., Mitani, S., Kudo, T., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105571 · Cited by 4
Drug-induced Pneumonitis Following the Administration of TAS-102
Hasegawa, Y., Ota, T., Tsukuda, H., Suzumura, T., & Fukuoka, M. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.6629 · Cited by 4
Botella, A. G., Gómez‐Bravo, M. Á., Martino, M. D., Gastaca, M., Martín‐Pérez, E., Sánchez-Cabús, S., Pérez, B. S., López‐Ben, S., Sanjuán, J. C. R., López‐Andújar, R., et al. (2020) · Cirugía Española · doi:10.1016/j.ciresp.2020.10.010 · Cited by 6
Signorelli, C., Gemma, D., Grande, R., Marco, S. D., Saltarelli, R., Morandi, M. G., Spinelli, G. P., Zoratto, F., Sperduti, I., Chilelli, M. G., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15033 · Cited by 4
A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea
Ando, T., Sakumura, M., Mihara, H., Fujinami, H., & Yasuda, I. (2022) · Healthcare · doi:10.3390/healthcare10020218 · Cited by 7
Kawakami, T., Masuishi, T., Kawamoto, Y., Go, H., Kato, K., Kumanishi, R., Sawada, K., Yuki, S., Yamamoto, K., Komatsu, Y., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4599 · Cited by 4
Self-citationWadd, N., Peedell, C., & Polwart, C. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.04.012 · Cited by 4
Was ist gesichert in der Therapie des Kolonkarzinoms
Lordick, F., Hacker, U. T., Hoffmeister, A., Bläker, H., & Gockel, I. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01419-4 · Cited by 6
Ding, P. Q., Dolley, A., & Cheung, W. Y. (2022) · Current Oncology · doi:10.3390/curroncol30010011 · Cited by 4
Amonkar, M. M., Abderhalden, L. A., Frederickson, A. M., Aksomaityte, A., Lang, B. M., Leconte, P., & Zhang, I. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04301-9 · Cited by 7
El-Bassiouny, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1112224 · Cited by 4
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1425 · Cited by 5
Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer
Victorino, A. P., Vieira, F. M. D. A. C., Mardegan, L., Festa-Vasconcellos, J. S., Piranda, D. N., & Araujo, K. B. (2023) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2023.101477 · Cited by 4
Dumont, F., Képénékian, V., Passot, C., Ezanno-Manasterski, A.-C., Pocard, M. D., Raoul, J., Lelièvre, B., Hiret, S., Senellart, H., Pein, F. J. L., et al. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108468 · Cited by 4
Target Therapy in Unresectable or Metastatic Colorectal Cancer
Kim, J. H., & Park, S. J. (2016) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2016.68.6.303 · Cited by 4
Metastatic Colorectal Cancer: Management With Trifluridine/Tipiracil
White, T. A., Larson, H., Minnella, A., & Höchster, H. S. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.e30-e37 · Cited by 4
Kim, K.-R., Yoon, J., Shim, H., Hwang, J., Bae, W., Chung, I., Kim, H. N., Shin, M., & Cho, S. (2017) · Oncology Letters · doi:10.3892/ol.2017.6414 · Cited by 4
Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients
Donadon, M., Cortese, N., Marchesi, F., Cimino, M., Mantovani, A., & Torzilli, G. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.03.06 · Cited by 5
Matsuoka, K., & Takechi, T. (2017) · PubMed Central · Cited by 4
Takeuchi, N., Koike, K., Yoshida, S., & Fujiwara, M. (2019) · Oncology Letters · doi:10.3892/ol.2019.11043 · Cited by 6
Oshima, K., Hirano, H., Shoji, H., Iwasa, S., Okita, N. T., Takashima, A., & Boku, N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269115 · Cited by 4
S-1 with leucovorin for gastric cancer: how far can it go?
Liu, T., & Chen, L. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00478-7 · Cited by 4
Management of patients with colorectal liver metastasis in eleven questions and answers
Andrès, A., Majno, P. E., Terraz, S., Morel, P., Roth, A. D., Rubbia‐Brandt, L., Schiffer, E. R. C., Ris, F., & Toso, C. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1249855 · Cited by 4
Yoshino, T., Hyodo, I., Nishina, T., Narahara, H., Sugimoto, N., Yoshisue, K., & Boku, N. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3212-6 · Cited by 4
Self-citationNoel, M. S. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.05.03 · Cited by 4
Unseld, M., Fischöder, S., Jachs, M., Drimmel, M., Siebenhüner, A. R., Bianconi, D., Kieler, M., Puhr, H. C., Minichsdorfer, C., Winder, T. L., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061772 · Cited by 4
Liver background uptake of [18F]FLT in PET imaging.
Sergeeva, O., Zhang, Y., Kenyon, J. D., Miller-Atkins, G. A., Sergeev, M. E., Verbus, E. A., Iyer, R. V., Sexton, S., Kepe, V., Avril, N. E., et al. (2020) · PubMed · Cited by 4
Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro
Bijnsdorp, I. V., & Peters, G. J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.21 · Cited by 4
Tamaki, S., Ishikawa, H., Suzuki, K., Kimura, Y., Maemoto, R., Abe, I., Endo, Y., Kakizawa, N., Watanabe, F., Futsuhara, K., et al. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2536 · Cited by 4
Li, J., Wang, Z., Huang, J., Ba, Y., Cao, B., Luo, S., Li, W., Bai, C., Song, Z., Xiong, J., et al. (2026) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(25)00267-5 · Cited by 3
Management of metastatic colorectal cancer in patients ≥70 years - a single center experience
Huemer, F., Dunkl, C., Rinnerthaler, G., Schlick, K., Heregger, R., Emmanuel, K., Neureiter, D., Klieser, E., Deutschmann, M., Roeder, F., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1222951 · Cited by 6
Karthaus, M., Heinemann, V., Riera‐Knorrenschild, J., Kretzschmar, A., Welslau, M., Kaiser, U., Pelz, H., Ettrich, T. J., Held, S., Kehmann, L., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12599-7 · Cited by 4
Lam, K. O., Li, K. H.-L., Leung, R. C.-Y., Tang, V., & Yau, T. C. C. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03077-4 · Cited by 3
Leng, W., Wen, Z., Wang, H., Cao, P., Liu, J., Luo, D., & Qiu, M. (2025) · BMC Cancer · doi:10.1186/s12885-025-13654-7 · Cited by 5
Desai, K. D., Amonkar, M. M., Jain, R., Patton, G., Estenson, K., Sartaj, A., Cosgrove, D., & Sura, S. D. (2025) · Future Oncology · doi:10.1080/14796694.2025.2504246 · Cited by 4
Sato, S., Nakayama, I., & Shitara, K. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2551748 · Cited by 4
Prager, G. W., Élez, E., Fakih, M., Ciardiello, F., Cutsem, E. V., Roby, L., Yao, W., Choucair, E., & Taïeb, J. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100234 · Cited by 3
Peng, Y., Wang, J., Wang, J., & Chen, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1670812 · Cited by 3
Yuan, J. T., Lou, S., Liu, Q., Wei, J., Sun, X., Sun, L., Yu, L., & Jiang, G. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04073-w · Cited by 3
Kang, W., Zhang, Z., Li, W., Zhang, Q., Li, N., Jiang, Y., Zhang, J., & He, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773002 · Cited by 3
Choo, J. R. E., Zhao, J. J., Lau, M. C., Raimondi, A., Yim, W. W., Ranganathan, S., Zhu, K., Tan, C. T. Y., Chin, H. X., Teo, C. B., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72204-2 · Cited by 3
Liposits, G. I., André, T., Aparicio, T., Montroni, I., Taïeb, J., Gallois, C., Cutsem, E. V., Ducreux, M. P., Pfeiffer, P., Lonardi, S., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00041-5 · Cited by 4
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.